EMS-Chemie stock trades on latest profit and revenue data
Published on 07/19/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EMS-Chemie (CH0016440353) is framed by its latest reported profit and revenue figures, even as the market side of the story remains tied to valuation rather than a fresh trading quote. The Swiss specialty chemicals group reported CHF 2.07 billion in net sales for full-year 2025 and CHF 551 million in operating cash flow, while EBIT reached CHF 543 million in 2025.
CHF 2.07 billion revenue
For 2025, EMS-Chemie reported net sales of CHF 2.07 billion and EBIT of CHF 543 million, which gives investors a clear read on the earnings base entering the new financial year. Operating cash flow came in at CHF 551 million in 2025, a second anchor that shows how profit converted into liquidity.
The comparison is also visible in the published figures: EBITDA stood at CHF 621 million in 2025, versus CHF 645 million in the prior year, while EBIT of CHF 543 million remained close to the same scale. That keeps the margin story central, because the company is still being valued more on durability than on volume growth alone.
Cash flow stayed high
Free cash flow was CHF 433 million in 2025, and the dividend for the year was proposed at CHF 18.00 per share. Those are the kinds of numbers that matter for a Swiss industrial stock with a reputation for balance-sheet strength and shareholder returns.
Another useful comparison is the net sales base itself: CHF 2.07 billion in 2025 followed a 2024 level of CHF 2.26 billion, showing that the latest year was smaller on revenue even as cash generation stayed solid. For readers tracking earnings quality, that split between sales and cash remains the key signal.
Product mix still matters
EMS-Chemie is still best read through its polymer and specialty materials mix, where the company has historically used higher-value applications rather than broad commodity exposure. That product structure is what allows a group with CHF 543 million in 2025 EBIT to hold investor attention even in a slower sales year.
For a company like EMS-Chemie, the market discussion usually centers on whether margin resilience can offset softer top-line momentum. The 2025 figures suggest that the answer depends less on headline growth and more on how efficiently the business converts sales into cash and earnings.
Cash and earnings remain
The latest reported numbers still define the stock: CHF 2.07 billion in sales, CHF 543 million in EBIT, and CHF 433 million in free cash flow in 2025. Those three figures, taken together, give a fuller picture than price alone and help explain why EMS-Chemie remains a valuation story as much as an operating one.
EMS-Chemie stock is listed in Switzerland, and the investment case is shaped by its earnings base, cash flow, and dividend discipline rather than by a single short-term catalyst. The latest published financial year is the reference point for any current reading of the shares.
EMS-Chemie at a glance
- Company: EMS-Chemie Holding AG
- ISIN: CH0016440353
- Ticker: SIX: EMSN
- Trading venue: SIX Swiss Exchange
- Sector / Industry: Materials / Specialty Chemicals
- Index membership: SMI
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
